Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1012878 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Xinyu Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Influenza Vaccines, Orthomyxoviridae Infections, Hemagglutinin Glycoproteins, Influenza Virus, Virion. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
One approach for developing a more universal influenza vaccine is to elicit strong immune responses against canonically immunosubdominant epitopes in the surface exposed viral glycoproteins. While standard vaccines typically induce responses directed primarily against mutable epitopes in the hemagglutinin (HA) head domain, there are generally limited or variable responses directed against epitopes in the relatively more conserved HA stalk domain and neuraminidase (NA) proteins. Here we describe a vaccine approach that utilizes a combination of wildtype (WT) influenza virus particles along with virus particles engineered to display a trimerized HA stalk in place of the full-length HA protein to elicit both responses simultaneously. After initially generating the “headless” HA-containing viral particles in the A/Hawaii/70/2019 (HI/19) genetic background and demonstrating the ability to elicit protective immune responses directed against the HA-stalk and NA, we co-formulated those virions with unmodified WT viral particles. The combination vaccine elicited “hybrid” and protective responses directed against the HA-head, HA-stalk, and NA proteins in both naïve and pre-immune mice and ferrets. Collectively, our results highlight a potentially generalizable method combining viral particles with differential antigenic compositions to elicit broader immune responses that may lead to more durable protection from influenza disease post-vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.
ORCID-Profile: Nicholas S Heaton
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Zhu, X., Luo, Z., Leonard, R. A., Hamele, C. E., Spreng, R. L., & Heaton, N. S. (2025). Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012878
Vancouver
Zhu X, Luo Z, Leonard RA, Hamele CE, Spreng RL, Heaton NS. Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012878
BibTeX
@article{Zhu2025,
author = {Zhu, Xinyu and Luo, Zhaochen and Leonard, Rebecca A and Hamele, Cait E and Spreng, Rachel L and Heaton, Nicholas S},
title = {Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1012878}
}
EUVIMED